SPTX (Seaport Therapeutics) Ending Cash Position: $46.50 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $24.04
! 2 Warning Signs
View Full Analysis

What is Seaport Therapeutics Ending Cash Position?

Seaport Therapeutics SPTX -0.99% 11 Ending Cash Position is $46.50 Mil as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Seaport Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was $46.50 Mil.

Seaport Therapeutics's quarterly Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($309.55 Mil) but then declined from Dec. 2024 ($309.55 Mil) to Dec. 2025 ($46.50 Mil).

Seaport Therapeutics's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($309.55 Mil) but then declined from Dec. 2024 ($309.55 Mil) to Dec. 2025 ($46.50 Mil).

Seaport Therapeutics Ending Cash Position Related Terms

Seaport Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics Ending Cash Position Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
Ending Cash Position
309.55 46.50

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
Ending Cash Position 309.55 46.50
SPTX
11GF Score
Seaport Therapeutics Inc SPTX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Seaport Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=309.553+-263.057
=46.50

Seaport Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=309.553+-263.057
=46.50

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $46.50 Mil mean?
Seaport Therapeutics (SPTX) has a Ending Cash Position of $46.50 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Seaport Therapeutics and its competitors.
Is Seaport Therapeutics' Ending Cash Position too high?
Seaport Therapeutics' current Ending Cash Position is $46.50 Mil. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' Ending Cash Position compare to SVRA and DRTS?
Seaport Therapeutics' Ending Cash Position of $46.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current Ending Cash Position is $46.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current Ending Cash Position of $46.50 Mil. The current Ending Cash Position is $46.50 Mil. Seaport Therapeutics' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current Ending Cash Position is $46.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.04
Price